A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Hypercholesterolaemia; Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Sponsors Viking Therapeutics
  • Most Recent Events

    • 22 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 22 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Jun 2018.
    • 08 Nov 2017 According to a Viking Therapeutics media release, the company expects to complete this trial in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top